Literature DB >> 3676830

Tolerance to morphine microinjections in the periaqueductal gray (PAG) induces tolerance to systemic, but not intrathecal morphine.

J A Siuciak1, C Advokat.   

Abstract

The acquisition and retention of tolerance to the antinociceptive effect of supraspinal morphine on the tail withdrawal reflex was assessed in rats implanted with unilateral cannulae in the periaqueductal gray (PAG). Development of tolerance to daily microinjections of morphine was indicated by the return of the tail flick response within 4 days, followed by the recovery of analgesic sensitivity one week later. After tolerance had developed, the effect of an acute systemic (1.5-4.5 mg/kg) or intrathecal (5-15 micrograms) morphine injection was determined. 'Cross-tolerance' was observed between systemic and supraspinal morphine but not between intrathecal and supraspinal morphine. The data indicate that tolerance to chronic intracerebral morphine produces the same behavioral consequences as tolerance to systemic morphine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3676830     DOI: 10.1016/0006-8993(87)91476-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

1.  Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.

Authors:  Tara A Macey; Erin N Bobeck; Deborah M Hegarty; Sue A Aicher; Susan L Ingram; Michael M Morgan
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

Review 2.  Endogenous opioid peptides in the descending pain modulatory circuit.

Authors:  Elena E Bagley; Susan L Ingram
Journal:  Neuropharmacology       Date:  2020-05-15       Impact factor: 5.250

3.  Tolerance to the antinociceptive effect of morphine in the absence of short-term presynaptic desensitization in rat periaqueductal gray neurons.

Authors:  Leon W Fyfe; Daniel R Cleary; Tara A Macey; Michael M Morgan; Susan L Ingram
Journal:  J Pharmacol Exp Ther       Date:  2010-08-25       Impact factor: 4.030

4.  Periaqueductal gray neuroplasticity following chronic morphine varies with age: role of oxidative stress.

Authors:  D Bajic; C B Berde; K G Commons
Journal:  Neuroscience       Date:  2012-09-19       Impact factor: 3.590

5.  Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the rat.

Authors:  Michael M Morgan; Erin N Bobeck; Susan L Ingram
Journal:  Brain Res       Date:  2009-08-05       Impact factor: 3.252

6.  Relative contribution of the dorsal raphe nucleus and ventrolateral periaqueductal gray to morphine antinociception and tolerance in the rat.

Authors:  Kyle N Campion; Kimber A Saville; Michael M Morgan
Journal:  Eur J Neurosci       Date:  2016-09-14       Impact factor: 3.386

7.  Transcutaneous electrical nerve stimulation at both high and low frequencies activates ventrolateral periaqueductal grey to decrease mechanical hyperalgesia in arthritic rats.

Authors:  J M DeSantana; L F S Da Silva; M A De Resende; K A Sluka
Journal:  Neuroscience       Date:  2009-07-02       Impact factor: 3.590

8.  Sexually dimorphic activation of the periaqueductal gray-rostral ventromedial medullary circuit during the development of tolerance to morphine in the rat.

Authors:  Dayna R Loyd; Michael M Morgan; Anne Z Murphy
Journal:  Eur J Neurosci       Date:  2008-03       Impact factor: 3.386

9.  Periaqueductal Gray and Rostromedial Tegmental Inhibitory Afferents to VTA Have Distinct Synaptic Plasticity and Opiate Sensitivity.

Authors:  Robyn St Laurent; Valentina Martinez Damonte; Ayumi C Tsuda; Julie A Kauer
Journal:  Neuron       Date:  2020-03-18       Impact factor: 17.173

10.  Supraspinal Gbetagamma-dependent stimulation of PLCbeta originating from G inhibitory protein-mu opioid receptor-coupling is necessary for morphine induced acute hyperalgesia.

Authors:  Enrica Bianchi; Monica Norcini; Alan Smrcka; Carla Ghelardini
Journal:  J Neurochem       Date:  2009-07-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.